Gufic BioSciences Ltd

Gufic BioSciences Ltd

₹ 355 -2.96%
14 Jun 4:01 p.m.
About

Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.

Key Points

History[1]
Gufic was in the business of manufacturing and marketing injectable products since late 1970s. The group had earlier exited its API and formulations manufacturing division by selling its six major brands such as Mox (Amoxycillin) Injection, Zole (Miconazole Nitrate) etc. to Ranbaxy in 1997. The promoters then re-entered pharmaceutical formulations segment through incorporation of Gufic Biosciences Limited in 2000.
Gufic Biosciences has been manufacturing lyophilized injectables (their main business) for 40+ years. It started with small base of 50,000 vials back in 2007-08 to right now almost 4 million vials per month.

  • Market Cap 3,573 Cr.
  • Current Price 355
  • High / Low 387 / 202
  • Stock P/E 41.5
  • Book Value 53.1
  • Dividend Yield 0.03 %
  • ROCE 16.9 %
  • ROE 19.6 %
  • Face Value 1.00

Pros

  • Company has delivered good profit growth of 31.5% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 27.0%
  • Company's median sales growth is 22.0% of last 10 years

Cons

  • Company might be capitalizing the interest cost
  • Debtor days have increased from 110 to 149 days.
  • Working capital days have increased from 122 days to 173 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
132 251 194 172 162 165 175 177 173 195 215 202 195
108 205 158 139 130 132 142 143 141 160 176 165 161
Operating Profit 24 46 36 33 33 33 33 34 32 35 39 36 34
OPM % 18% 18% 18% 19% 20% 20% 19% 19% 19% 18% 18% 18% 18%
1 1 0 2 0 0 1 1 1 1 0 0 1
Interest 3 1 2 1 1 1 2 2 3 4 4 3 4
Depreciation 4 4 4 4 5 4 5 6 6 4 4 4 4
Profit before tax 17 42 30 29 26 28 27 27 24 28 31 30 27
Tax % 25% 25% 23% 27% 23% 26% 26% 25% 24% 26% 25% 25% 26%
13 31 23 21 20 21 20 20 18 21 23 22 20
EPS in Rs 1.65 3.22 2.41 2.17 2.09 2.17 2.08 2.10 1.87 2.13 2.39 2.22 2.00
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
98 121 148 201 245 306 351 379 488 779 691 807
87 109 134 181 222 267 305 327 404 631 556 661
Operating Profit 11 12 14 20 23 39 46 52 84 148 135 146
OPM % 11% 10% 10% 10% 9% 13% 13% 14% 17% 19% 20% 18%
0 1 1 1 1 4 4 6 4 3 3 2
Interest 4 4 4 6 6 9 10 14 14 5 8 15
Depreciation 2 2 4 4 4 4 5 14 16 19 22 17
Profit before tax 5 6 7 10 14 30 35 30 58 127 107 116
Tax % 37% 32% 36% 29% 37% 45% 38% 25% 23% 24% 25% 26%
3 4 4 7 9 16 22 23 44 96 80 86
EPS in Rs 0.43 0.55 0.54 0.95 1.17 2.13 2.82 2.92 5.68 9.89 8.22 8.59
Dividend Payout % 12% 9% 9% 5% 4% 2% 2% 2% 2% 1% 1% 0%
Compounded Sales Growth
10 Years: 21%
5 Years: 18%
3 Years: 18%
TTM: 17%
Compounded Profit Growth
10 Years: 35%
5 Years: 32%
3 Years: 25%
TTM: 8%
Stock Price CAGR
10 Years: 47%
5 Years: 35%
3 Years: 25%
1 Year: 75%
Return on Equity
10 Years: 27%
5 Years: 27%
3 Years: 27%
Last Year: 20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 8 8 8 8 8 8 8 10 10 10 10 10
Reserves 15 18 19 26 30 46 68 120 164 259 338 523
35 33 33 43 57 80 98 126 62 64 334 333
32 52 67 75 84 104 106 152 157 188 179 227
Total Liabilities 90 111 127 152 178 238 280 408 392 521 861 1,093
27 30 25 22 22 23 24 83 100 115 160 159
CWIP 3 0 0 0 0 2 10 31 13 41 170 307
Investments 0 0 0 0 0 0 0 0 0 0 1 2
60 81 102 130 156 213 245 294 279 365 531 625
Total Assets 90 111 127 152 178 238 280 408 392 521 861 1,093

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
5 11 11 -4 -4 -5 5 47 87 106 -27 -7
-13 -3 -2 -1 -5 -9 -13 -43 -7 -95 -191 -102
8 -7 -5 5 7 14 8 -4 -79 -6 234 82
Net Cash Flow 0 1 4 -0 -1 1 -0 0 2 5 17 -27

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 75 85 82 102 78 97 107 103 93 71 109 149
Inventory Days 143 144 165 180 190 238 190 249 138 102 202 188
Days Payable 144 176 223 188 132 192 157 238 162 125 143 156
Cash Conversion Cycle 74 54 25 94 136 143 141 114 69 48 167 181
Working Capital Days 71 64 48 76 84 109 128 110 80 58 136 173
ROCE % 18% 17% 18% 24% 24% 33% 30% 21% 29% 46% 23%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
65.13% 75.48% 75.48% 75.48% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 72.51% 72.51%
0.14% 1.52% 1.69% 1.51% 1.38% 0.06% 0.16% 0.72% 0.70% 0.72% 0.47% 0.12%
3.24% 2.13% 1.19% 1.12% 1.13% 1.16% 1.16% 1.16% 1.16% 1.63% 1.72% 2.20%
31.49% 20.87% 21.64% 21.89% 22.49% 23.76% 23.67% 23.12% 23.12% 22.64% 25.29% 25.17%
No. of Shareholders 43,88335,13534,58038,14440,12041,37640,56238,90238,62436,55734,42434,695

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls